Harnessing the benefits of available targeted therapies in acute myeloid leukaemia
- 20 October 2021
- journal article
- review article
- Published by Elsevier in The Lancet Haematology
- Vol. 8 (12) , e922-e933
Abstract
No abstract availableKeywords
This publication has 70 references indexed in Scilit:
- Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid LeukemiaJournal of Clinical Oncology, 2012
- Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabineProceedings of the National Academy of Sciences, 2010
- Anthracycline Dose Intensification in Acute Myeloid LeukemiaNew England Journal of Medicine, 2009
- High-Dose Daunorubicin in Older Patients with Acute Myeloid LeukemiaNew England Journal of Medicine, 2009
- Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98BHaematologica, 2009
- Evolution of decitabine developmentCancer, 2008
- A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatmentCancer, 2007
- Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemiaBlood, 2006
- Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trialBlood, 2006
- Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemiaLeukemia, 2004